Screener
Recursion Pharmaceuticals, Inc. RXRX Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $7.67M-60.1% | $6.47M-56.1% | $35.54M+682% | $5.18M-80.2% | $19.22M+33.3% | ||
| $11.49M-43.0% | $12.49M-42.8% | $14.28M+11.6% | $14.69M+21.6% | $20.16M+119% | ||
| -$3.82M-307% | -$6.02M+15.0% | $21.26M— | -$9.51M-168% | -$938K-118% | ||
| -49.8%-44.9pp | -93%-44.9pp | 59.8%— | -183.8%-237pp | -4.9%-41.1pp | ||
| $89.61M-30.3% | $87.9M-32.2% | $95.94M-2.4% | $121.06M+62.3% | $128.64M+74.0% | ||
| $41.53M-11.0% | $34.59M-36.7% | $33.66M-56.4% | $41.63M+10.3% | $46.65M+46.6% | ||
| $142.64M-27.0% | $134.98M-34.5% | $143.87M-23.6% | $177.38M+42.5% | $195.45M+70.0% | ||
| -$134.97M+23.4% | -$128.51M+32.8% | -$108.33M+41.0% | -$172.2M-75.1% | -$176.23M-75.3% | ||
| -1,759.7%-843pp | -1,985.6%-688pp | -304.8%+3,738pp | -3,327.6%-2,950pp | -916.8%-219pp | ||
| $3.96M-8.5% | $6.4M+157% | $232K-95.2% | $9.95M+271% | $4.33M+74.6% | ||
| -$131.01M+23.8% | -$122.11M+39.7% | -$108.1M+39.6% | -$162.25M-69.6% | -$171.9M-75.3% | ||
| -$1K— | -$4.6M-2,814% | —— | $3K-98.2% | $0+100% | ||
| -$131.01M+23.8% | -$117.5M+42.0% | -$108.12M+39.6% | -$162.25M-69.3% | -$171.9M-76.2% | ||
| -1,708%-814pp | -1,815.6%-442pp | -304.2%+3,631pp | -3,135.3%-2,768pp | -894.2%-218pp | ||
| -$0.25+39.0% | -$0.22+56.0% | -$0.17+70.2% | -$0.36-5.9% | -$0.41-2.5% | ||
| -$116.8M+23.3% | -$108.83M+36.7% | -$88.86M+48.0% | -$151.16M-65.8% | -$152.38M-66.4% | ||
| -1,522.8%-730pp | -1,681.6%-515pp | -250%+3,507pp | -2,920.9%-2,571pp | -792.7%-157pp | ||
| -$134.97M+23.4% | -$128.51M+32.8% | -$108.33M+41.0% | -$172.2M-75.1% | -$176.23M-75.3% |
FAQ
- What is Recursion Pharmaceuticals, Inc.'s revenue?
- Recursion Pharmaceuticals, Inc. (RXRX) generated $54.9M in revenue over the trailing twelve months, down 15.1% year over year.
- Is Recursion Pharmaceuticals, Inc. profitable?
- Recursion Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $518.9M over the trailing twelve months, a -945.9% net margin.
- What are Recursion Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 3.5% and operating margin is -991.7%, with a -945.9% net margin.
- What is Recursion Pharmaceuticals, Inc.'s earnings per share?
- Recursion Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-1.00.
- Where does Recursion Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Recursion Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
